Page 120 - MEMORIA ANUAL 2019 SEHH-FEHH

MEMORIA ANUAL 2019
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
• Recasens V, Ropero P, Lacalle L, Rodríguez-Vigil C, Montañés A, González FA, Pinzón S, Paúl P, Yus F, Rubio R, Díez R, Gómez A, Bustamante E. Capillary electro- phoresis and mutational images of hemoglobin sendagi [Β42 (CD1) PHE → VAL; HBB: C.127T→G]. Clin Biochem. 2019 Sep;71:69-71. doi: 10.1016/j.clinbio- chem.2019.07.006.
• Ropero P, González FA, Nieto JM, Villegas A, Sevilla J, Pérez G, Alonso JM, Reca- sens V, Abio M, Vagace JM, Vanegas RJ, González Fernández B, Martínez R. C>A substitution in NT 46 of the 3’ UTR region (the α complex protected region) of the alpha-1 globin gene: a non-deletional mutation or polymorphism? J Clin Pathol. 2020 Jan;73(1):14-6. doi: 10.1136/jclinpath-2019-206004.
• Mora A, Ayala L, Bielza R, Ataúlfo González F, Villegas A. Improving safety in blood transfusion using failure mode and effect analysis. Transfusion. 2019 Feb;59(2):516-23. doi: 10.1111/trf.15137.
• Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, González-Fernán- dez FA, Gaya A, Lee JW, Gutiérrez EO, Piatek CI, Szer J, Risitano A, Nakao S, Bach- man E, Shafner L, Damokosh AI, Ortiz S, Röth A, Peffault de Latour R. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019 Feb 7;133(6):540-9. doi: 10.1182/blood-2018-09-876805.
• Kulasekararaj A, Hill A, Langemeijer S, Wells R, González-Fernández FA, Gaya A, Ojeda-Gutiérrez E, Piatek CI, Mitchell LD, Usuki K, Bosi A, Brodsky RA, Ogawa M, Yu J, Ortiz S, Röth A, Lee JW, Peffault de Latour R. One-Year Efficacy and Safety from a phase 3 trial of Ravulizumab in adult patients with paroxysmal Nocturnal he- moglobinuria receiving prior Eculizamab treatment. Blood. 2019;134(1):2231-6.
• Muñoz G, García-Seisdedos D, Ciubotariu C, Piris-Villaespesa M, Gandía M, Martín-Moro F, Gutiérrez-Solana LG, Morado M, López-Jiménez J, Sánchez-He- rranz A, Villarrubia J, Del Castillo FJ. Early detection of lysosomal diseases by screening of cases of idiopathic splenomegaly and/or thrombocytopenia with a next-generation sequencing gene panel. JIMD Rep. 2019 Dec 1;51(1):53-61. doi: 10.1002/jmd2.12078.
• Moreno-Carralero MI, Arrizabalaga-Amuchastegui B, Sánchez-Calero-Guilarte J, Morado-Arias M, Velasco-Valdazo AE, de-la-Iglesia-Íñigo S, Méndez M, Morán-Jimé- nez MJ. Missense variants in ALAS2 gene in five patients. Int J Lab Hematol. 2019 Feb;41(1):e5-e9. doi: 10.1111/ijlh.12902.
GRUPO ESPAñOL DE ERITROPATOLOGÍA (GEE)
120